Laparoscopy can prevent futile primary cytoreductive surgery

January 6, 2017

(HealthDay)—Diagnostic laparoscopy reduces the number of futile laparotomies in women with suspected advanced-stage ovarian cancer, according to a study published online Dec. 28 in the Journal of Clinical Oncology.

Marianne J. Rutten, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues conducted a that involved eight gynecologic centers. Patients with suspected advanced-stage ovarian cancer who qualified for primary cytoreductive surgery (PCS) were randomly assigned to either (102 patients) or primary surgery (99 patients). Laparoscopy guided selection of primary treatment (primary surgery or neoadjuvant chemotherapy followed by interval surgery). Futile laparotomy, defined as a PCS with residual disease of >1 cm, was the primary outcome.

The researchers found that 63 of 102 patients in the laparoscopy group underwent PCS versus 93 of 99 patients in the primary surgery group. Futile laparotomy occurred in 10 percent of those in the laparoscopy group versus 39 percent in the primary surgery group (relative risk, 0.25). Three percent of patients in the laparoscopy group underwent both primary and interval surgery versus 28 percent of patients in the primary surgery group.

"In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to <1 cm of residual disease seems feasible, to proceed with PCS," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: Laparoscopic approach in early-stage ovarian cancer promising

More information: Full Text

Related Stories

Laparoscopic approach in early-stage ovarian cancer promising

August 13, 2013
(HealthDay)—Operative outcomes of laparoscopic approach in patients with early-stage ovarian cancer may be comparable with those of laparotomy, according to a meta-analysis published in the July issue of the American Journal ...

Neoadjuvant chemotherapy use up in ovarian cancer treatment

September 12, 2016
(HealthDay)—For patients with stage IIIC to IV ovarian cancer, neoadjuvant chemotherapy (NACT) use increased from 2003 to 2012, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Surgery, chemo best for elderly with advanced ovarian cancer

December 29, 2015
(HealthDay)—Primary debulking surgery and chemotherapy in an optimal timeframe is associated with the longest survival time for elderly women with advanced ovarian cancer, according to a study published in the January issue ...

Recs developed for neoadjuvant chemo in ovarian cancer

August 9, 2016
(HealthDay)—Guidelines have been developed for neoadjuvant chemotherapy use for newly diagnosed, advanced ovarian cancer. The clinical practice guideline was published online Aug. 8 in the Journal of Clinical Oncology.

Robotic surgery may be superior to laparoscopic for uterine CA

November 18, 2015
(HealthDay)—For women with uterine cancer, robotic surgery is more costly but is associated with decreased length of hospital stay and higher rate of lymph node dissection, according to a study published in the November ...

Benefits of single-incision laparoscopy unclear

August 2, 2013
(HealthDay)—There is limited data available to demonstrate the safety and feasibility of minimally invasive, single-incision laparoscopy, according to a technology assessment published in the August issue of Obstetrics ...

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.